KR20230107301A - 오피오이드 치료들을 위한 항체들 - Google Patents

오피오이드 치료들을 위한 항체들 Download PDF

Info

Publication number
KR20230107301A
KR20230107301A KR1020237019397A KR20237019397A KR20230107301A KR 20230107301 A KR20230107301 A KR 20230107301A KR 1020237019397 A KR1020237019397 A KR 1020237019397A KR 20237019397 A KR20237019397 A KR 20237019397A KR 20230107301 A KR20230107301 A KR 20230107301A
Authority
KR
South Korea
Prior art keywords
seq
antibody
amino acid
cdr
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237019397A
Other languages
English (en)
Korean (ko)
Inventor
킴 디. 잔다
폴 티. 브레머
빈 조우
Original Assignee
더 스크립스 리서치 인스티튜트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 스크립스 리서치 인스티튜트 filed Critical 더 스크립스 리서치 인스티튜트
Publication of KR20230107301A publication Critical patent/KR20230107301A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Addiction (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020237019397A 2020-11-10 2021-11-08 오피오이드 치료들을 위한 항체들 Pending KR20230107301A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063111699P 2020-11-10 2020-11-10
US63/111,699 2020-11-10
PCT/US2021/058459 WO2022103700A1 (en) 2020-11-10 2021-11-08 Antibodies for opioid treatments

Publications (1)

Publication Number Publication Date
KR20230107301A true KR20230107301A (ko) 2023-07-14

Family

ID=81601678

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237019397A Pending KR20230107301A (ko) 2020-11-10 2021-11-08 오피오이드 치료들을 위한 항체들

Country Status (10)

Country Link
US (1) US20230399418A1 (https=)
EP (1) EP4244256A4 (https=)
JP (1) JP7839789B2 (https=)
KR (1) KR20230107301A (https=)
CN (1) CN116745318A (https=)
AU (1) AU2021377609A1 (https=)
CA (1) CA3200523A1 (https=)
IL (1) IL302673A (https=)
MX (1) MX2023005032A (https=)
WO (1) WO2022103700A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3267132A1 (en) * 2022-09-09 2024-03-14 Regents Of The University Of Minnesota ANTIBODIES DIRECTED AGAINST FENTANYL AND ITS ANALOGUES AND THEIR METHODS OF USE

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200808822A (en) * 2006-04-14 2008-02-16 Amgen Inc Erythropoietin receptor agonists
WO2013095091A2 (en) * 2011-11-17 2013-06-27 Aimm Therapeutics B.V. Rsv g protein specific antibodies
AU2017345786B2 (en) * 2016-10-21 2024-08-01 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
WO2018140821A1 (en) * 2017-01-26 2018-08-02 Surrozen, Inc. Tissue-specific wnt signal enhancing molecules and uses thereof
EP3880698A4 (en) * 2018-11-14 2022-11-30 RubrYc Therapeutics, Inc. MANIPULATED CD25 POLYPEPTIDES AND USES THEREOF

Also Published As

Publication number Publication date
WO2022103700A1 (en) 2022-05-19
MX2023005032A (es) 2023-05-16
CN116745318A (zh) 2023-09-12
US20230399418A1 (en) 2023-12-14
EP4244256A4 (en) 2024-12-25
AU2021377609A1 (en) 2023-06-08
IL302673A (en) 2023-07-01
CA3200523A1 (en) 2022-05-19
JP2023548603A (ja) 2023-11-17
AU2021377609A9 (en) 2024-09-26
JP7839789B2 (ja) 2026-04-02
EP4244256A1 (en) 2023-09-20

Similar Documents

Publication Publication Date Title
JP7391510B2 (ja) ヒト化抗ｃｄ７３抗体
JP6437922B2 (ja) Ｂｃｍａ抗原結合タンパク質
JP7665098B2 (ja) 多重特異性抗体およびその使用
JP7607564B2 (ja) Ｐｍｅｌ１７に対する抗体及びその結合体
KR102132604B1 (ko) 비형 간염 표면 항원에 대한 항체 및 그의 용도
KR102561555B1 (ko) Ｂ형 간염 감염 및 관련 질병의 치료를 위한 항체
KR20230107301A (ko) 오피오이드 치료들을 위한 항체들
CN114423454A (zh) 抗类胰蛋白酶抗体的给药
RU2841257C1 (ru) Антитела для лечения опиоидной зависимости
JP5963233B2 (ja) Ｈｔｌｖ−１関連脊髄症を治療または予防するための医薬および前記医薬を用いた抗体療法の治療効果の確認方法
CN115197323A (zh) 一种sn38抗体或其抗原结合片段及其应用
AU2024316626A1 (en) Anti-ror1 protein antibody and conjugate thereof
WO2024044722A1 (en) Drip-antibodies and use thereof
HK40067775A (en) Dosing for anti-tryptase antibodies
HK40112252A (en) Antibodies to pmel17 and conjugates thereof
JP2025108586A (ja) 多重特異性抗体およびその使用
JP2025036273A (ja) 多重特異性抗体およびその使用

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230608

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20241106

Comment text: Request for Examination of Application